Dementia and Alzheimer Disease

Epilepsy

Headache and Migraine

Movement Disorders

Multiple Sclerosis

Neuromuscular

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

eNewsletter

Print Subscription

Videos

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital provided insight on new updates to the management of restless legs syndrome, including removing dopamine agonists as first line treatments. [WATCH TIME: 8 minutes]

Critical Updates to the Treatment of Restless Legs Syndrome: John Winkelman, MD, PhD

Articles

The study did not meet its primary end point of change from baseline in Performance of the Upper Limb 2.0 score at 1 year.

FibroGen's Duchenne Muscular Dystrophy Antibody Pamrevlumab Falls Short in Phase 3

At the conclusion of the analysis, lemborexant was shown to be safe, with significant improvements seen in REM latency, total REM sleep, and other measures.

Lemborexant Continues to Show Efficacious Profile in Obstructive Sleep Apnea Without Insomnia

Preclinical findings show the potential of samelisant, a potent and orally active Histamine H3 receptor inverse agonist, as a potential treatment for patients with Parkinson disease who experience excessive daytime sleepiness. 

Samelisant Shows Potential as a Treatment for Excessive Daytime Sleepiness in Parkinson Disease

Vice Chairman, Department of Neurology; Director, Movement Disorders Program; 

Medical Director, Georgetown University Hospital National Parkinsonism Foundation Center of Excellence; 

Medical Director, Translational Neurotherapeutics Program; 

Associate Professor, Department of Neurology, Georgetown University

The course directors of the 2023 ATRMD Congress provided an overview of the upcoming meeting, and the educational benefits clinicians can gain from attending. [WATCH TIME: 6 minutes]

Reasons to Attend the 2023 Advanced Therapeutics in Movement & Related Disorders Congress: Fernando Pagan, MD; Yasar Torres-Yaghi, MD

, has been with the team since September 2022. Follow her on Twitter 

Carolyn H. Goldschmidt, DO, a neurologist at NorthShore University Health System in Chicago, talked about a retrospective study analyzing disease-modifying therapies in multiple sclerosis patients at CMSC 2023.

Bridging the Gap, De-Escalation of MS Disease Modifying Therapies: Carolyn H Goldschmidt, DO

Neurologist, Oregon Health State University

The professor of neurology at Oregon Health & Science University talked about a study on a modified low-fat diet intervention and its effects on fatigue in patients with multiple sclerosis over a 16-week period at CMSC 2023. [WATCH TIME: 8 minutes] 

Investigating the Impact of a Low-Fat Diet on Quality of Life and Symptom Management in MS: Vijayshree Yadav, MD, MCR, FANA, FAAN

Patients with multiple sclerosis who presented with high-stress maintained their stress management practice through later protocol sessions, according to a study a recent study.

Stress Management Protocol Reduces Depression and Anxiety in Patients With MS: Amy Sullivan, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Jesus Eric Pina-Garza, MD

Articles